Abstract | BACKGROUND: OBJECTIVE: METHODS: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Patients with type 2 DM who were taking a stable dose of pioglitazone or rosiglitazone and had a glycosylated hemoglobin (HbA1c) value < or =9.0% and an LDL-C concentration > 100 mg/dL were randomized to receive simvastatin 40 mg (the recommended initial dose for patients with DM) or placebo for 24 weeks. The primary end point was the effect of treatment on LDL-C concentrations. Other lipid, lipoprotein, and safety measures were also assessed. RESULTS: Two hundred fifty-three patients (127 [50.2%] men, 126 [49.8%] women; mean age, 56 years) were randomized to treatment (123 simvastatin, 130 placebo). At the end of the study, mean LDL-C concentrations were reduced 34.)% from baseline (from 134.3 to 89.5 mg/dL) in the simvastatin group and were unchanged in the placebo group (P<0.001). Simvastatin produced significant reductions in concentrations of total cholesterol, triglycerides (TG), non- high-density lipoprotein cholesterol, and apolipoprotein ( apo) B compared with placebo (all, P<0.001 ) and significant increases in concentrations of high-density lipoprotein cholesterol (HDL-C) ( P=0.002 ) and apo A-I ( P=0.006 ). In patients who had not attained target concentrations of LDL-C (<100 mg/dL), TG (<150 mg/dL), or HDL-C (>45 mg/dL) at baseline, significantly more simvastatin recipients had achieved these goals at the end of the study compared with placebo recipients ( LDL-C: 67.3% vs 5.2%, respectively, P<0.001; HDL-C: 95.3% vs 83.6%, P<0.05; TG: 40.8% vs 11.0%, P<0.001 ). Simvastatin was well tolerated, and no clinically meaningful differences in the incidence of serious adverse events, treatment-related adverse events, or discontinuations due to adverse events were observed between groups. There were no significant between-group differences in glycemic control (HbA1c) or concentrations of fasting insulin, creatine phosphokinase, or hepatic transaminases. CONCLUSION:
Simvastatin was an effective and generally well tolerated treatment for hyperlipidemia when used in combination with TZD therapy in this population of patients with type 2 DM.
|
Authors | Andrew J Lewin, Mark S Kipnes, Luigi F Meneghini, Diane J Plotkin, Inna T Perevozskaya, Sukrut Shah, Darbie L Maccubbin, Yale B Mitchel, Jonathan A Tobert, Simvastatin/Thiazolidinedione Study Group |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 26
Issue 3
Pg. 379-89
(Mar 2004)
ISSN: 0149-2918 [Print] United States |
PMID | 15110130
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Thiazolidinediones
- Rosiglitazone
- Simvastatin
- Pioglitazone
|
Topics |
- Adult
- Aged
- Cholesterol, LDL
(blood)
- Diabetes Mellitus, Type 2
(drug therapy)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hyperlipoproteinemias
(drug therapy)
- Male
- Middle Aged
- Pioglitazone
- Rosiglitazone
- Simvastatin
(therapeutic use)
- Thiazolidinediones
(therapeutic use)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|